Device billed as smallest, lightest responsive therapy for drug-resistant epilepsy
The SenTiva implantable generator and Vagus Nerve Stimulation (VNS) Therapy Programming System (LivaNova USA) have received FDA approval for the treatment of patients with drug-resistant epilepsy.
SenTiva is the smallest and lightest responsive therapy for epilepsy, LivaNova says. The new VNS Therapy Programming System features a wireless wand and new user interface on a small tablet. Together, the components offer patients with drug-resistant epilepsy a physician-directed customizable therapy with smart technology and proven results to reduce the number of seizures, lessen the duration of seizures, and enable a faster recovery, LivaNova says.
SenTiva’s compact size allows for a more comfortable experience for pediatric patients; VNS Therapy is the first system that is FDA approved for drug-resistant epilepsy in children as young as 4 years of age. SenTiva is also the first epilepsy device of its size to include detect-and-respond mode, designed to prevent seizures before they start and automatically deliver extra therapy to stop them if they do. SenTiva also collects and logs events commonly associated with seizures, including a patient’s body position and heart rate variations.
The VNS Therapy Programming System is compatible not only with , but with all LivaNova legacy VNS Therapy generators, allowing physicians to use the system with numerous patients. When combined with SenTiva’s technology, the new system provides several advanced options and personalized features, including guided programming, scheduled programming, and day and night programming by physicians.
“Since every patient suffering from seizures is different, we need more treatment options. SenTiva and the VNS Therapy Programming System will provide that additional flexibility and customization for our patients,” said Dr. James Wheless, Professor and Chief of Pediatric Neurology of Le Bonheur Children’s Hospital in Memphis, Tennessee.
The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications.
Source: LivaNova
